sub:assertion {
d:DB00188 dv:ddi-interactor-in dr:DB00188_DB00758 .
d:DB00758 dv:ddi-interactor-in dr:DB00188_DB00758 .
dr:DB00188_DB00758 dcterms:identifier "drugbank_resource:DB00188_DB00758" ;
dcterms:title "DDI between Bortezomib and Clopidogrel - Moderate CYP2C19 Inhibitors like bortezomib may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Avoid concurrent use of moderate CYP2C19 inhibitors with clopidogrel whenever possible. If such a combination must be used, monitor closely for evidence of reduced clinical response to clopidogrel."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Bortezomib and Clopidogrel - Moderate CYP2C19 Inhibitors like bortezomib may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Avoid concurrent use of moderate CYP2C19 inhibitors with clopidogrel whenever possible. If such a combination must be used, monitor closely for evidence of reduced clinical response to clopidogrel. [drugbank_resource:DB00188_DB00758]"@en .
}